Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ. Bijker N, et al. Among authors: duchateau l. J Clin Oncol. 2001 Apr 15;19(8):2263-71. doi: 10.1200/JCO.2001.19.8.2263. J Clin Oncol. 2001. PMID: 11304780 Clinical Trial.
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Klijn JG, et al. Among authors: duchateau l. J Clin Oncol. 2001 Jan 15;19(2):343-53. doi: 10.1200/JCO.2001.19.2.343. J Clin Oncol. 2001. PMID: 11208825
Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854.
van der Hage JA, van de Velde CJ, Julien JP, Floiras JL, Delozier T, Vandervelden C, Duchateau L. van der Hage JA, et al. Among authors: duchateau l. Eur J Cancer. 2001 Nov;37(17):2184-93. doi: 10.1016/s0959-8049(01)00294-5. Eur J Cancer. 2001. PMID: 11677105 Clinical Trial.
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Biganzoli L, et al. Among authors: duchateau l. J Clin Oncol. 2002 Jul 15;20(14):3114-21. doi: 10.1200/JCO.2002.11.005. J Clin Oncol. 2002. PMID: 12118025 Clinical Trial.
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A, Hamilton A, Piccart M. Biganzoli L, et al. Among authors: duchateau l. Cancer. 2003 Jan 1;97(1):40-5. doi: 10.1002/cncr.10914. Cancer. 2003. PMID: 12491503 Free article. Clinical Trial.
481 results